



## FOR IMMEDIATE RELEASE

### **Immgenuity, Inc. Enters Into a Scientific Collaboration Agreement with Biostax Corp.**

Dover, Delaware, August 14, 2023 - Immgenuity, Inc., a leading biotechnology company focused on developing innovative immunotherapy for HIV to effect remission, announced today that it has entered into a scientific collaboration agreement with Biostax Inc., formerly Immune Therapeutics, Inc..

Under the terms of the agreement, Immgenuity and Biostax will collaborate to advance the development of novel immunotherapies for the treatment of HIV and other diseases. The collaboration will leverage Immgenuity's expertise in developing cutting-edge technologies for the identification and characterization of immune cell populations, mechanisms of immune escape, and Biostax's deep knowledge and experience in using low-dose Naltrexone (LDN) as an immune enhancing agent.

"We are excited to partner with Biostax, a renowned company with a strong track record of innovation in the fields of HIV and cancer," said Dr. Sateesh Apte, CEO of Immgenuity. "By combining our respective strengths and expertise, we believe we can make significant progress in the development of new immunotherapies that can address HIV persistence, NeuroAIDS and improve patient outcomes. Research on our therapeutic vaccine for HIV, IMTV014, will be greatly enhanced by our collaboration with Biostax."

The collaboration will be led by Immgenuity's and Biostax's Chief Scientific Officers. The teams will work closely together to advance the research program and identify new approaches and clinical strategies.

"We are thrilled to partner with Immgenuity on this important initiative," said Noreen Griffin, CEO of Biostax. "This collaboration has the potential to accelerate the development of new immunotherapies that can make a meaningful difference in the lives of patients with HIV."

### **About Immgenuity, Inc.**

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

### **About IMTV014**

Immgenuity's immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by

the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as “salvage therapy” in the multidrug resistant population.

### **About Biostax**

Biostax Corp. is a pioneering pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a well-defined path to market. By utilizing a biotech portfolio hub-and-spoke engine, the company plans to advance focused and efficient small-scale biotechnology and pharmaceutical programs through subsidiaries, investment vehicles, or partnerships, and deploy its products from those programs in markets both in the U.S. and internationally for initial commercialization.

Contact: Media Relations: [media@immgenuity.com](mailto:media@immgenuity.com) (302) 321-5844

### Forward Looking Statements:

This press release contains “forward-looking statements” within the meaning of federal securities law, including statements concerning the company’s outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.